<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04782999</url>
  </required_header>
  <id_info>
    <org_study_id>H-7-2014-010</org_study_id>
    <nct_id>NCT04782999</nct_id>
  </id_info>
  <brief_title>Effect of RYGB on Alpha- and Beta Cell Function and Sensitivity to Incretins in Patients With Type 2 Diabetes</brief_title>
  <acronym>BETASIN</acronym>
  <official_title>Effect of RYGB on Alpha- and Beta Cell Function and Sensitivity to Incretins in Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hvidovre University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hvidovre University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to investigate the effect of Roux-en-Y gastric bypass (RYGB) on&#xD;
      pancreatic alpha and beta-cell function and for the sensitivity of incretin hormones in&#xD;
      patients with pre-operative type 2 diabetes.&#xD;
&#xD;
      Primary hypotheses:&#xD;
&#xD;
        -  After RYGB, the sensitivity to GLP-1 and GIP is improved (improved insulinotropic&#xD;
           effect).&#xD;
&#xD;
        -  After RYGB, the insulin secretion improves during an oral glucose tolerance test within&#xD;
           3 months postoperatively.&#xD;
&#xD;
        -  After RYGB, the insulin secretion during intraveneous stimulation with glucose or&#xD;
           non-glucose (arginin) is unchanged.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Design: 12 patients with type 2 diabetes will be recruited.&#xD;
&#xD;
      All subjects will undergo 11 study visits: four visits before, three visits at 1 week after&#xD;
      surgery and four visits at 3 months postoperatively:&#xD;
&#xD;
        -  Oral glucose tolerance tests (OGTTs) with measurement of GLP-1 and GIP secretion will be&#xD;
           performed before and 3 months post-surgery.&#xD;
&#xD;
        -  Hyperglycemic clamps with co-infusion of saline, GLP-1 or GIP will be performed in a&#xD;
           randomised order at three separate study visits in randomized order before, 1 week and 3&#xD;
           months after surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2015</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective evaluation of gastric bypass patients, who will be examined before, 1 week and 3 months after the gastric bypass operation.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulinotropic effects of GLP-1 and GIP</measure>
    <time_frame>Change from before to 1 week and 3 months after RYGB</time_frame>
    <description>Insulin secretion during steady state of all hyperglycemic clamps</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulin secretion during oral stimulation</measure>
    <time_frame>Change from before to 3 month after RYGB</time_frame>
    <description>AUC of C-peptide during oral glucose tolerance test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulin secretion during iv stimulation</measure>
    <time_frame>Change from before to 1 week and 3 months after RYGB</time_frame>
    <description>Insulin secretion during hyperglycemic clamp with saline infusion and during argininine iv stimulation test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Alpha cell function</measure>
    <time_frame>Change from before to after 1 week and 3 months after RYGB</time_frame>
    <description>Glucagon secretion during hyperglycemic clamps</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Type2 Diabetes</condition>
  <condition>Obesity, Morbid</condition>
  <arm_group>
    <arm_group_label>Oral glucose tolerance test</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral glucose tolerance test with ingestion of 75 g glucose and blood sampling.&#xD;
This test will be performed before and 3 months after RYGB.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hyperglycemic clamp with saline infusion combined with arginine test</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hyperglycemic clamp with blood glucose kept at 15 mmol/L by adjustable infusions of intraveneous glucose for 120 min with co-infusion of saline.&#xD;
After 120 min an arginine test with infusion of 50 g Arginine is performed.&#xD;
This test will be performed before, 1 week and 3 months after RYGB.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hyperglycemic clamp with GLP-1 infusion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hyperglycemic clamp with blood glucose kept at 15 mmol/L by adjustable infusion of intraveneous glucose for 90 min with co-infusion of GLP-1.&#xD;
This test will be performed before, 1 week and 3 months after RYGB.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hyperglycemic clamp with GIP infusion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hyperglycemic clamp with blood glucose kept at 15 mmol/L by adjustable infusions of intraveneous glucose for 90 minutes with co-infusion of GIP.&#xD;
This test will be performed before, 1 week and 3 months after RYGB.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Oral Glucose Tolerance Test</intervention_name>
    <description>Standard test of glucose tolerance with ingestion of 75 g glucose followed by blood sampling.</description>
    <arm_group_label>Oral glucose tolerance test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Hyperglycemic clamp with infusion of saline, GLP-1 or GIP</intervention_name>
    <description>Blood glucose kept at 15 mmol/L via iv 20% glucose infusions.&#xD;
Primed co-infusion of either:&#xD;
Saline&#xD;
GLP-1 (Prime dose 6 pmol/kg, infusion 1 pmol/kg/min)&#xD;
GIP (Prime dose 3 pmol/kg, infusion 1.5 pmol/kg/min).</description>
    <arm_group_label>Hyperglycemic clamp with GIP infusion</arm_group_label>
    <arm_group_label>Hyperglycemic clamp with GLP-1 infusion</arm_group_label>
    <arm_group_label>Hyperglycemic clamp with saline infusion combined with arginine test</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Inclusion criteria for RYGB in Denmark (ie. BMI &gt; 35 in the presence of obesity&#xD;
             related co-morbidities as type 2 diabetes)&#xD;
&#xD;
          -  Type 2 diabetes&#xD;
&#xD;
          -  Pre-operative: Fasting plasma glucose ≥7,0 mmol/L or 2 hour plasma glucose ≥ 11,1&#xD;
             mmol/L (after pausing antidiabetic medication for a minimum of 3 days)&#xD;
&#xD;
          -  Written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Exclusion criteria for RYGB (psychiatric illness, obesity triggered by medical&#xD;
             treatment for psychiatric illness, mental retardation, alcohol or drug abuse, severe&#xD;
             heart-lung disease despite optimal medical treatment, previous serious problems with&#xD;
             universal anesthesia, previous peritonitis, large hiatus hernia, diseases of the&#xD;
             ventricle / previously complicated upper abdominal surgery, recurrent esophagitis,&#xD;
             poor compliance).&#xD;
&#xD;
          -  Type 2 diabetes where antidiabetic medication cannot be paused for 3 days.&#xD;
&#xD;
          -  Pregnancy and breast-feeding.&#xD;
&#xD;
          -  Hemoglobin &lt;7.0 mmol/L&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Maria Svane, MD, PhD</last_name>
    <email>Maria.saur.svane@regionh.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hvidovre University Hospital</name>
      <address>
        <city>Hvidovre</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Svane, MD, PhD</last_name>
      <email>Maria.Saur.Svane@regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Morten Hindsøe, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 26, 2021</study_first_submitted>
  <study_first_submitted_qc>March 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2021</study_first_posted>
  <last_update_submitted>March 2, 2021</last_update_submitted>
  <last_update_submitted_qc>March 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hvidovre University Hospital</investigator_affiliation>
    <investigator_full_name>Maria Saur Svane</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Obesity, Morbid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

